Basic Information
Lunsumio
Regulatory Information
EMEA/H/C/005680
June 3, 2022
April 22, 2022
6
October 22, 2024
Company Information
Germany
Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen
Roche Registration GmbH
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
Overview Summary
Lunsumio is a cancer medicine used to treat adults with follicular lymphoma that does not respond to (refractory) or has come back (relapsed) after at least two previous treatments. Follicular lymphoma is rare, and Lunsumio was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 November 2021. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/EU3212517](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2517) Lunsumio contains the active substance mosunetuzumab.